By contrast, the new gene therapy only requires a single dose, and most patients in the study did not need to resume prophylactic factor IX treatments. "We hear from people born with hemophilia ...
If used for the management of AVD, speak with a specialist to make an informed choice. In addition, people may experience temporary AVD, leading to hypernatremia. Tapering the dose after the blood ...
The first dose, which is much smaller, prepares the immune system to respond more powerfully to the second, larger dose. This study, which was performed by bringing together computational modeling ...